Milestone Scientific Inc

This management proposal asks stockholders to approve an amendment to the Company’s Restated Certificate of Incorporation to increase authorized common shares from 125 million to 135 million. Management frames the request as a measure to ensure the Company has sufficient authorized shares to meet contractual obligations, settle recently granted performance-based awards, and to permit future financings, stock-based compensation, strategic transactions, and other corporate purposes without convening a special stockholder meeting. The Company discloses the current outstanding shares and a detailed breakdown of shares issuable upon exercise of warrants, options, PRSUs, deferred compensation and shares available under the equity plan to justify the incremental capacity. The Board emphasizes that the additional shares will have the same rights as existing common stock and that approval will not immediately dilute voting power but could enable issuances that reduce existing shareholders’ ownership percentages. The filing notes potential anti-takeover implications—while management states there is no present intent to use the shares offensively, approval could facilitate defensive issuances in the future. The Board recommends a “FOR” vote, arguing prompt access to authorized shares provides strategic and financial flexibility and avoids the time and cost of a special meeting. The proposal requires a simple majority of votes cast and broker non-votes will not be counted; the Board also reserves the right not to proceed with filing even if approved. In evaluating this item an analyst should weigh the Company’s stated operational need to settle committed awards and pursue financings against the potential dilution risk and governance considerations related to broad share authorization.

Management requests shareholder approval to more than double the share reserve under the 2020 Equity Incentive Plan—adding 17.25 million shares to raise the cap to 28.75 million—to ensure the Company can continue to grant options, restricted stock, and the newly created performance-based restricted stock units (PRSUs). The Compensation Committee has already granted PRSUs that, if performance milestones are met, could require settlement of more than 11.2 million shares; management states the current reserve is insufficient to cover those awards and ongoing equity needs. The proposal is positioned as a standard corporate governance action to preserve the Company’s ability to attract, retain and motivate employees and executives via equity compensation, align management and stockholder interests, and conserve cash by using equity in lieu of cash compensation. The Board emphasizes the rationale based on historical usage, planned PRSU awards, and anticipated hiring/granting activity and recommends a ‘‘FOR’’ vote to avoid termination of granted awards or a halt in equity grants. From a governance and dilution perspective, an analyst should consider the dilutive impact—management provided basic dilution metrics and historical issuance rates—and weigh them against the strategic need to incentivize executives, especially given sizable grants to recent hires and executives. The filing notes that broker non-votes will not affect the outcome and that a simple majority of votes cast is required for approval. In evaluating the merits, assess the performance conditions of PRSUs, vesting and forfeiture terms, and whether the share issuance pace is sustainable relative to corporate performance and shareholder value creation.

This non-binding management proposal asks shareholders to approve, on an advisory basis, the compensation paid to the named executive officers as disclosed in the proxy statement. Management describes the program as intended to attract and retain leadership, reward performance, and align executives’ interests with long-term shareholder value through base salary, performance-based bonuses, and equity awards. The Board notes recent changes intended to strengthen pay-for-performance alignment, including repricings and new PRSUs and equity grants tied to performance milestones. Although advisory, the Compensation Committee and the Board will consider the vote’s outcome when making future compensation decisions; abstentions count as against for effect. For an analyst, critical evaluation should compare realized pay (CAP) to company performance metrics disclosed (net loss, TSR), examine the size and terms of recent equity grants (including repriced options and large PRSU awards to executives), and consider potential dilution and retention benefits. The Board recommends a “FOR” vote, arguing that the disclosed policies and recent compensation actions better align management incentives with shareholder interests; however, shareholders should weigh the magnitude and structure of recent grants relative to company performance and governance norms. This is a routine advisory corporate governance item in today’s markets but may carry reputational implications if defeated, which could prompt Board/Compensation Committee actions.